오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - codeine phosphate hemihydrate, quantity: 10 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate; purified talc; maize starch; povidone - for the temporary relief of acute moderate pain and fever

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; macrogol 6000; titanium dioxide; povidone; magnesium stearate; maize starch; propylene glycol; sodium starch glycollate; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - metformin hydrochloride -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - simvastatin -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - loratadine, quantity: 1 mg/ml - oral liquid - excipient ingredients: propylene glycol; purified water; sodium benzoate; glycerol; edetate sodium; maltitol solution; citric acid monohydrate; menthol; sucralose; flavour - for use in children 1-12 years of age for relief of the symptoms of seasonal and non-seasonal allergic rhinitis, such as sneezing, nasal discharge and itching, and ocular itching and burning, and chronic urticaria (hives)..

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - excipient ingredients: - diacare tablets,when taken as directed, provide effective relief from diarrhoea. o.r.s oral rehydration salts help manage dehydration due to diarrhoea and traveller's gastroenteritis.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe andogenetic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. it is thus possible to treat diseases in women caused either by increases production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if meditab cyproterone is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. this also promotes regular menstruation. . men: reduction of drive in sexual deviations. meditab cyproterone reduces the force of the sexual urge in men with sexual deviations. whilst under treatment, the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. meditab cyproterone therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation. inoperable prostatic carcinoma. to suppress "flare" with initial lhrh analogue therapy. in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy..

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - aciclovir - concentrate for solution for infusion - 25 milligram(s)/millilitre - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

yamanouchi pharma ltd - unknown

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

yamanouchi pharma ltd - cream